COMMUNIQUÉS West-GlobeNewswire

Syneos Health Introduces New Book, Why We Resist: The Surprising Truths About Motivating Behavior Change

30/09/2019 - 13:30

Syneos Health Behavioral Scientist and Expert Communicator Team Up to Author Behavioral Insights Book – Proceeds Donated to The STARR Coalition MORRISVILLE, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Syneos Health ® ( [...]

TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib (“U2”) in Blood

30/09/2019 - 13:30

U2 combination was generally well-tolerated with relatively low rates of immune-mediated toxicities Combination treatment resulted in median progression free survival (PFS) of ~28 months in relapsed/refractory chronic [...]

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

30/09/2019 - 13:16

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON, Sept. 30, 2019 (GLOBE [...]

Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

30/09/2019 - 13:03

EVANSTON, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]

Orchard Therapeutics Announces Presentation of New Clinical Data for OTL-200 for Metachromatic Leukodystrophy at Upcoming European Society of Gene & Cell Therapy Annual Congress

30/09/2019 - 13:00

Initial Results from Cryopreserved Formulation Clinical Trial Accepted as Poster Presentation BOSTON and LONDON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage [...]

ProQR to Present at Two Investor Conferences in October

30/09/2019 - 13:00

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]

R1 RCM to Present at the Cantor Fitzgerald 2019 Global Healthcare Conference

30/09/2019 - 13:00

CHICAGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leader in technology-enabled revenue cycle management (RCM) services to healthcare providers, today announced the company will present at the [...]

Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

30/09/2019 - 13:00

PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in May of this year. [...]

FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis

30/09/2019 - 13:00

-- Novel Human Antibody Targets CTGF, A Central Mediator in Fibrosis -- SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced publication in The Lancet Respiratory Medicine of [...]

Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation

30/09/2019 - 13:00

SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in transthyretin (TTR) [...]

Kalos Therapeutics, Inc., Oncology Pharmaceuticals and NanoSmart Pharmaceuticals, Inc., Combination Therapy Offers the Potential of a Safer and More Effective Approach to a Wide Variety of Cancer Treatments

30/09/2019 - 12:30

SAN FRANCISCO, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that Kalos Therapeutics' lead compound, KTH-222, can produce a reduction in the attachment of [...]

Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations

30/09/2019 - 12:30

DURHAM, N.C., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering, proprietary [...]

BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019

30/09/2019 - 12:00

CAMBRIDGE, Mass. and BEIJING, China, Sept. 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]

Ambu A/S: Financial Diary

30/09/2019 - 10:18

Ambu Financial Diary 2019/20 and 2020/21 Attachment Company Announcement no 16 2018_19

MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress

30/09/2019 - 09:20

ROCKVILLE, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]

ASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies

30/09/2019 - 08:35

- ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to US$5 million - ASLAN and Bukwang will co-own new entity to develop novel pre-clinical AhR [...]

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

30/09/2019 - 08:30

Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal Phase III ALEX [...]

NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER

30/09/2019 - 08:30

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER Paris & Boston, September 30, 2019 – 08h30am CEST - Neovacs (Euronext Growth Paris: ALNEV), a [...]

NÉOVACS ANNONCE LA NOMINATION DE VINCENT SERRA EN QUALITÉ DE DIRECTEUR GÉNÉRAL

30/09/2019 - 08:30

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS ANNONCE LA NOMINATION DE VINCENT SERRA EN QUALITÉ DE DIRECTEUR GÉNÉRAL Paris et Boston, le 30 septembre 2019 – 08h30 CEST - Néovacs (Euronext [...]